Publication at Faculty of Medicine in Hradec Králové |
2021
Abstract
The results of ATTRACTION-3 study demonstrated a benefit of nivulumab in comparison to the standard chemotherapy in the treatment of advanced/metastatic esophageal squamous cell carcinoma after a failure of platinum and fluoropyrimidine therapy. Based on this study, nivolumab has become a standard of second-line palliative systemic therapy.
The results of CheckMate 577 study, published recently, demostrated a benefit of nivolumab also in an adjuvant indication in patients with previous neoadjuvant chemoradiotherapy and curative surgery.